文献速递妇科生殖医学

子宫动脉确定性阻断对腹腔镜子宫肌瘤剔除术患者卵巢储备标志物的影响:一项随访2年的随机对照试验

Impact of definitive uterine artery occlusion on ovarian reserve markers in laparoscopic myomectomy: a randomized controlled trial with 2-year follow-up.
PubMed 文献 · Hum Reprod · 2025-01-01

这项随机对照试验纳入58例FIGO 3至6型症状性子宫肌瘤拟行腹腔镜子宫肌瘤剔除术的育龄女性,评估预防性子宫动脉确定性阻断对卵巢储备标志物的短期和长期影响。结果显示,UAO组术中平均出血量138±104 ml,对照组为436±498 ml(P<0.001);两组各时间点血清AMH水平均无差异,非劣效界值为-3.5 pmol/l。

要点

  • 预防性UAO可减少腹腔镜子宫肌瘤剔除术中的出血量。
  • UAO组与对照组在术后1、3、6、12、24个月的血清AMH水平均无差异。
  • UAO组和对照组的AFC在各时间点均无差异,但未能证明非劣效性。

核心结论

  • 预防性子宫动脉确定性阻断不损害卵巢储备标志物,可安全用于改善育龄女性腹腔镜子宫肌瘤剔除术的围手术期出血控制。

研究设计与样本

  • 随机对照试验,纳入58例FIGO 3至6型症状性子宫肌瘤拟行腹腔镜子宫肌瘤剔除术的育龄女性,于2015年7月至2021年10月招募,随访2年。
  • 患者随机分为UAO组(腹腔镜子宫肌瘤剔除术加预防性子宫动脉阻断,n=29)和no-UAO组(腹腔镜子宫肌瘤剔除术不阻断子宫动脉但肌层内注射血管收缩剂,n=29)。
  • 术前分配对手术医生披露,女性对整个研究期间的分组设盲。
  • 在基线(T0)及术后1个月(T1)、3个月(T3)、6个月(T6)、12个月(T12)和24个月(T24)评估血清AMH水平和AFC。

主要发现

  • 术中平均出血量UAO组为138±104 ml,no-UAO组为436±498 ml(P<0.001)。
  • 术中出血量>500 ml的比例UAO组为0%,no-UAO组为32.1%(P<0.01)。
  • 两组血清AMH水平在各时间点均无差异,均值差及95%CI分别为:T1 -0.11(-2.14至2.40)、T3 -0.25(-2.36至2.21)、T6 0.81(-2.69至3.84)、T12 -0.95(-3.15至1.33)、T24 1.18(-1.95至3.82)。
  • 预防性阻断在非劣效界值-3.5 pmol/l下被证明非劣效。
  • 两组AFC在各时间点均无差异,但未能证明预防性阻断的非劣效性,原文推测可能与该测量变异大有关。

关键数值与推荐

  • AMH非劣效界值为-3.5 pmol/l。
  • 术中出血量>500 ml的比例UAO组0% vs no-UAO组32.1%(P<0.01)。

临床怎么用

  • 作者认为,腹腔镜子宫肌瘤剔除术中预防性UAO不损害卵巢储备标志物,可安全用于改善育龄女性的围手术期出血控制。
  • 作者认为,将UAO作为腹腔镜子宫肌瘤剔除术中的预防措施可能提高手术安全性。

局限性

  • 样本量计算基于检测血清AMH水平至少三分之二SD的临床相关差异,但不能排除更大样本量可能揭示对血清AMH的较小影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does definitive occlusion of uterine arteries have a short- or long-term impact on ovarian reserve markers in reproductive-age women undergoing laparoscopic myomectomy? SUMMARY ANSWER: Preventive definitive uterine artery occlusion (UAO) during laparoscopic myomectomy reduces intraoperative blood loss but does not impact serum AMH levels after short- and long-term follow-up in reproductive-age women. WHAT IS KNOWN ALREADY: Uterine leiomyomas are the most common benign tumours in women of reproductive age. For symptomatic women willing to retain their uterus, especially for a future pregnancy, the current gold standard is surgical myomectomy for subserous/intramural leiomyoma. Temporary or definitive occlusion of uterine arteries can be performed to control bleeding during surgery but its impact on ovarian reserve markers is still unclear. A single randomized trial with a 1-year follow-up demonstrated that temporary bilateral UAO during laparoscopic myomectomy slightly decreased AMH levels at postoperative day 2 but has no significant impact at 3, 6, and 12 months after surgery. STUDY DESIGN, SIZE, DURATION: We conducted a randomized controlled trial with a 2-year follow-up evaluating the effect of definitive occlusion of uterine arteries on ovarian reserve markers via sequential measures of AMH levels and AFC by ultrasound assessment. The study included 58 women with symptomatic leiomyoma type FIGO 3 to 6 scheduled for laparoscopic myomectomy between July 2015 and October 2021. Patient allocation was disclosed to the surgeon just before starting the procedure; women were blinded to group allocation throughout the study. PARTICIPANTS/MATERIALS, SETTING, METHODS: Patients were randomized in two groups: the UAO group (laparoscopic myomectomy with preventive occlusion of uterine arteries) (n = 29 women) and the no-UAO group (laparoscopic myomectomy without occlusion of uterine arteries but with intra-myometrial injection of vasoconstrictive agents) (N = 29 women). Serum AMH levels and AFC were evaluated at baseline (T0) and followed at 1 month (T1), 3 months (T3), 6 months (T6), 12 months (T12), and 24 months (T24) after surgery. Intraoperative blood loss, evolution of uterine bleeding and pain symptoms, and leiomyoma recurrence were also evaluated as secondary outcomes. Pregnancies and live births were monitored. MAIN RESULTS AND THE ROLE OF CHANCE: Women in both groups did not differ in their baseline characteristics in terms of age, body mass index, ethnicity, parity, wish to become pregnant, hormonal treatment, leiomyoma number and size, baseline haemoglobin levels, uterine bleeding symptoms, baseline serum AMH levels, and AFC. The mean operative time was similar between both groups. Mean blood loss during surgery was on average 138 (±104) ml in the UAO group versus 436 (±498) ml in controls (P < 0.001). In the UAO group, 0% had an intraoperative blood loss >500 ml versus 32.1% in the no-UAO group (P < 0.01). Regarding clinical symptoms, most patients in both groups had decreased menstrual flow at the last follow-up visit (24 months) compared to baseline and improvement of dysmenorrhea followed the same trend with a reduction in pain levels in both groups. The risk of leiomyoma recurrence was similar between both groups. Serum AMH levels did not differ between the groups at any time (T1, T3, T6, T12, and T24) and non-inferiority of preventive occlusion was demonstrated with a non-inferiority margin of [-3.5 pmol/l]. Differences between means and 95% CI (in parentheses) were as follows: at T1 -0.11 (-2.14 to 2.40), at T3 -0.25 (-2.36 to 2.21), at T6 0.81 (-2.69 to 3.84), at T12 -0.95 (-3.15 to 1.33), and at T24 1.18 (-1.95 to 3.82). AFC did not differ between the groups at any time, however, non-inferiority of preventive occlusion could not be demonstrated, presumably due to a large variability in this measurement. LIMITATIONS, REASONS FOR CAUTION: Our sample size was calculated to detect a clinically relevant difference of at least two-thirds of the SD in serum AMH levels, but we cannot exclude that a larger sample size might have revealed a smaller impact on serum AMH. WIDER IMPLICATIONS OF THE FINDINGS: Preventive UAO during laparoscopic myomectomy does not compromise ovarian reserve markers and can be used safely to improve perioperative bleeding control in women of reproductive age. Incorporating UAO as a preventive measure during laparoscopic myomectomy may enhance the safety of the procedure. STUDY FUNDING/COMPETING INTEREST(S): Funded by the Department of Paediatrics, Gynecology and Obstetrics of the Geneva University Hospitals. There are no competing interests to declare. TRIAL REGISTRATION NUMBER: NCT02563392. TRIAL REGISTRATION DATE: 9 July 2015. DATE OF FIRST PATIENT’S ENROLMENT: July 2015.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Streuli I, Ramyead L, Silvestrini N, et al. Impact of definitive uterine artery occlusion on ovarian reserve markers in laparoscopic myomectomy: a randomized controlled trial with 2-year follow-up. Hum Reprod. 2025. PMID: 40420404. doi:10.1093/humrep/deaf070

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。